ClinicalTrials.gg
CompletedNCT06112756NIRVANAUpdated Nov 10, 2025Results posted

A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause

A Phase 2 interventional study of Elinzanetant and Placebo in Sleep Disturbances Associated With Menopause, sponsored by Bayer. Completed at 40 sites in 7 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause.

Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life.

The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances.

The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo.

For this, the researchers will analyze

  • change in the total number of minutes a participant wakes up at night after going to sleep after 4 weeks of treatment compared to before treatment
  • change in the total number of minutes a participant wakes up at night after going to sleep after 12 weeks of treatment compared to before treatment
  • change in the participant's total time asleep while in bed after 4 and 12 weeks of treatment compared to before treatment.

The study participants will be randomly (by chance) assigned to one of two treatment groups. Dependent on the group, they will take elinzanetant or placebo for 12 weeks.

Each participant will be in the study for approximately 22 weeks (plus potential washout period), including a screening phase of up to 6 weeks, 12 weeks of treatment, and a follow up phase of 4 weeks after the end of treatment. 5 visits to the study site are planned.

During the study, the doctors and their study team will:

  • take blood and urine samples
  • do physical examinations
  • check vital signs
  • do sleep tests
  • use an electronic hand-held device to record sleep quality and hot flashes at home

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

02

Conditions studied

  • Sleep Disturbances Associated With Menopause
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged 40 to 65 years, inclusive, at signing of .
  • Being in the period, defined as: serum FSH levels >40 mIU/mL and a serum estradiol concentration of \<30 pg/mL at screening, AND Hysterectomy performed at least 6 weeks prior to screening.
  • The participant's self-reported sleep history includes ongoing sleep disturbances associated with menopause characterized by waking up at night and/or poor quality of sleep.
  • WASO of 30 minutes or more (mean of 2 screening PSGs with neither of the 2 nights \<20 min).

Exclusion criteria

Exclusion Criteria:

  • Medical history, or baseline PSG assessment, includes a diagnosis of a sleep disorder other than sleep disturbances associated with the menopause (e.g., sleep apnea, restless leg syndrome, circadian rhythm sleep disorder).
  • Current or history (except complete remission for 5 years or more) of any (except basal and squamous cell skin tumors).
  • Renal impairment greater than moderate (i.e. estimated \<30 mL/min/1.73 m\^2) at screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Elinzanetant arm

    Participants will take Elinzanetant

    Drug: Elinzanetant

  • Placebo comparator
    Placebo arm

    Participants will take elinzanetant matching placebo

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)

    WASO is defined as total time (min) spent awake from onset of persistent sleep to lights on. Persistent sleep is defined as 20 consecutive epochs (10 min) of non wakefulness. Smaller WASO values indicate shorter periods of wakefulness after sleep onset.

    Time frame: From baseline until week 4

Secondary outcomes

  1. Change From Baseline in WASO at Week 12 as Measured by PSG

    WASO is defined as total time (min) spent awake from onset of persistent sleep to lights on. Persistent sleep is defined as 20 consecutive epochs (10 min) of non wakefulness. Smaller WASO values indicate shorter periods of wakefulness after sleep onset.

    Time frame: From baseline until week 12

  2. Change From Baseline in Sleep Efficiency (SE) at Week 4 as Measured by PSG

    Sleep efficiency is defined as the percentage of time spent asleep while in bed. (Total sleep time / time in bed) x 100. Higher sleep efficiency values indicate more time spent asleep.

    Time frame: From baseline to Week 4

  3. Change From Baseline in SE at Week 12 as Measured by PSG

    Sleep efficiency is defined as the percentage of time spent asleep while in bed. (Total sleep time / time in bed) x 100. Higher sleep efficiency values indicate more time spent asleep.

    Time frame: From baseline to week 12

  4. Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 4

    Participants' responses to the 8 items of the instrument are scored on a 1-5 numeric rating scale and will be aggregated to derive total raw scores ranging from 8-40 with higher scores indicating greater severity of sleep disturbance. These total raw scores will be converted into T-scores for comparison with population norms (United States general population). T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population.

    Time frame: From baseline until week 4

  5. Change From Baseline inPatient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 12

    Participants' responses to the 8 items of the instrument are scored on a 1-5 numeric rating scale and will be aggregated to derive total raw scores ranging from 8-40 with higher scores indicating greater severity of sleep disturbance. These total raw scores will be converted into T-scores for comparison with population norms (United States general population). T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population.

    Time frame: From baseline until week 12

  6. Change From Baseline in Insomnia Severity Index (ISI) Total Score at Week 4

    Insomnia Severity Index (ISI): The ISI is a 7-item tool that measures insomnia severity over the past two weeks (Bastien et al., 2001). It evaluates sleep onset, maintenance issues, early morning awakenings, satisfaction with sleep, noticeability of problems, distress caused, and daytime interference. Scoring: The ISI uses a 5-point Likert scale (0 to 4). Item scores are summed to yield a total score ranging from 0 to 28. Severity Categories: 0-7: No clinically significant insomnia (better outcome) 8-14: Subthreshold insomnia (moderate outcome) 15-21: Clinical insomnia (moderate severity) (worse outcome) 22-28: Clinical insomnia (severe) (worse outcome) Interpretation: Higher total scores indicate worse insomnia severity, while lower scores indicate better sleep quality. The total score is the sum of individual item scores.

    Time frame: From baseline until week 4

  7. Change From Baseline in ISI Total Score at Week 12

    Insomnia Severity Index (ISI): The ISI is a 7-item tool that measures insomnia severity over the past two weeks (Bastien et al., 2001). It evaluates sleep onset, maintenance issues, early morning awakenings, satisfaction with sleep, noticeability of problems, distress caused, and daytime interference. Scoring: The ISI uses a 5-point Likert scale (0 to 4). Item scores are summed to yield a total score ranging from 0 to 28. Severity Categories: 0-7: No clinically significant insomnia (better outcome) 8-14: Subthreshold insomnia (moderate outcome) 15-21: Clinical insomnia (moderate severity) (worse outcome) 22-28: Clinical insomnia (severe) (worse outcome) Interpretation: Higher total scores indicate worse insomnia severity, while lower scores indicate better sleep quality. The total score is the sum of individual item scores.

    Time frame: From baseline until week 12

07

Results

Posted Nov 10, 2025

Participant flow

The study was conducted at 39 study centers, of which 30 centers had randomized participants in Europe and the US. In the US, separate sleep laboratories were used by 9 sites that did not have polysomnography (PSG) capability.

Participant flow — Overall Study
MilestoneElinzanetantPlacebo
Started5555
Completed5251
Not completed34
Withdrew: Withdrawal by subject02
Withdrew: Subject took an out of state job and had to early terminate10
Withdrew: Adverse event22

Outcome measures

PrimaryChange From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)

WASO is defined as total time (min) spent awake from onset of persistent sleep to lights on. Persistent sleep is defined as 20 consecutive epochs (10 min) of non wakefulness. Smaller WASO values indicate shorter periods of wakefulness after sleep onset.

Time frame:
From baseline until week 4
Reported as:
Least squares mean · Minutes
Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)
MinutesElinzanetantPlacebo
Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)-23.50 ± 4.63-1.01 ± 4.68
SecondaryChange From Baseline in WASO at Week 12 as Measured by PSG

WASO is defined as total time (min) spent awake from onset of persistent sleep to lights on. Persistent sleep is defined as 20 consecutive epochs (10 min) of non wakefulness. Smaller WASO values indicate shorter periods of wakefulness after sleep onset.

Time frame:
From baseline until week 12
Reported as:
Least squares mean · Minutes
Change From Baseline in WASO at Week 12 as Measured by PSG
MinutesElinzanetantPlacebo
Change From Baseline in WASO at Week 12 as Measured by PSG-16.48 ± 4.64-15.54 ± 4.76
SecondaryChange From Baseline in Sleep Efficiency (SE) at Week 4 as Measured by PSG

Sleep efficiency is defined as the percentage of time spent asleep while in bed. (Total sleep time / time in bed) x 100. Higher sleep efficiency values indicate more time spent asleep.

Time frame:
From baseline to Week 4
Reported as:
Mean · Percentage
Change From Baseline in Sleep Efficiency (SE) at Week 4 as Measured by PSG
PercentageElinzanetantPlacebo
Change From Baseline in Sleep Efficiency (SE) at Week 4 as Measured by PSG6.85 ± 8.071.13 ± 10.31
SecondaryChange From Baseline in SE at Week 12 as Measured by PSG

Sleep efficiency is defined as the percentage of time spent asleep while in bed. (Total sleep time / time in bed) x 100. Higher sleep efficiency values indicate more time spent asleep.

Time frame:
From baseline to week 12
Reported as:
Mean · Percentage
Change From Baseline in SE at Week 12 as Measured by PSG
PercentageElinzanetantPlacebo
Change From Baseline in SE at Week 12 as Measured by PSG5.15 ± 9.684.67 ± 8.10
SecondaryChange From Baseline in Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 4

Participants' responses to the 8 items of the instrument are scored on a 1-5 numeric rating scale and will be aggregated to derive total raw scores ranging from 8-40 with higher scores indicating greater severity of sleep disturbance. These total raw scores will be converted into T-scores for comparison with population norms (United States general population). T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population.

Time frame:
From baseline until week 4
Reported as:
Mean · T-Score
Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 4
T-ScoreElinzanetantPlacebo
Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 4-11.17 ± 8.04-6.59 ± 6.76
SecondaryChange From Baseline inPatient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 12

Participants' responses to the 8 items of the instrument are scored on a 1-5 numeric rating scale and will be aggregated to derive total raw scores ranging from 8-40 with higher scores indicating greater severity of sleep disturbance. These total raw scores will be converted into T-scores for comparison with population norms (United States general population). T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population.

Time frame:
From baseline until week 12
Reported as:
Mean · T-Score
Change From Baseline inPatient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 12
T-ScoreElinzanetantPlacebo
Change From Baseline inPatient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 12-14.66 ± 9.36-6.65 ± 8.29
SecondaryChange From Baseline in Insomnia Severity Index (ISI) Total Score at Week 4

Insomnia Severity Index (ISI): The ISI is a 7-item tool that measures insomnia severity over the past two weeks (Bastien et al., 2001). It evaluates sleep onset, maintenance issues, early morning awakenings, satisfaction with sleep, noticeability of problems, distress caused, and daytime interference. Scoring: The ISI uses a 5-point Likert scale (0 to 4). Item scores are summed to yield a total score ranging from 0 to 28. Severity Categories: 0-7: No clinically significant insomnia (better outcome) 8-14: Subthreshold insomnia (moderate outcome) 15-21: Clinical insomnia (moderate severity) (worse outcome) 22-28: Clinical insomnia (severe) (worse outcome) Interpretation: Higher total scores indicate worse insomnia severity, while lower scores indicate better sleep quality. The total score is the sum of individual item scores.

Time frame:
From baseline until week 4
Reported as:
Mean · Scores on a scale
Change From Baseline in Insomnia Severity Index (ISI) Total Score at Week 4
Scores on a scaleElinzanetantPlacebo
Change From Baseline in Insomnia Severity Index (ISI) Total Score at Week 4-7.8 ± 6.0-4.7 ± 4.8
SecondaryChange From Baseline in ISI Total Score at Week 12

Insomnia Severity Index (ISI): The ISI is a 7-item tool that measures insomnia severity over the past two weeks (Bastien et al., 2001). It evaluates sleep onset, maintenance issues, early morning awakenings, satisfaction with sleep, noticeability of problems, distress caused, and daytime interference. Scoring: The ISI uses a 5-point Likert scale (0 to 4). Item scores are summed to yield a total score ranging from 0 to 28. Severity Categories: 0-7: No clinically significant insomnia (better outcome) 8-14: Subthreshold insomnia (moderate outcome) 15-21: Clinical insomnia (moderate severity) (worse outcome) 22-28: Clinical insomnia (severe) (worse outcome) Interpretation: Higher total scores indicate worse insomnia severity, while lower scores indicate better sleep quality. The total score is the sum of individual item scores.

Time frame:
From baseline until week 12
Reported as:
Mean · ISI total score
Change From Baseline in ISI Total Score at Week 12
ISI total scoreElinzanetantPlacebo
Change From Baseline in ISI Total Score at Week 12-9.8 ± 6.4-6.9 ± 5.6

Adverse events

Collected over After the first study intervention up to 113 days until the last follow-up visit. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BAY 3427080 / Elinzanetant0/55 (0%)0/55 (0%)24/55 (43.6%)
Placebo0/55 (0%)2/55 (3.6%)25/55 (45.5%)
Most frequent serious events
Most frequent serious events
EventBAY 3427080 / ElinzanetantPlacebo
DiverticulitisInfections and infestations0/551/55
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/551/55
Most frequent other events
Showing 10 of 51
Most frequent other events
EventBAY 3427080 / ElinzanetantPlacebo
HeadacheNervous system disorders5/556/55
FatigueGeneral disorders4/550/55
GastroenteritisInfections and infestations0/553/55
Abdominal pain upperGastrointestinal disorders2/551/55
Urinary tract infectionInfections and infestations2/550/55
COVID-19Infections and infestations1/552/55
Alanine aminotransferase increasedInvestigations0/552/55
Gamma-glutamyltransferase increasedInvestigations0/552/55
ArthralgiaMusculoskeletal and connective tissue disorders2/551/55
Back painMusculoskeletal and connective tissue disorders2/550/55

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ElinzanetantPlaceboTotal
Mean54.8 ± 4.654.9 ± 4.754.8 ± 4.6
Sex/Gender, Customized
Sex/Gender, Customized(Participants)ElinzanetantPlaceboTotal
Female5555110
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ElinzanetantPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American14923
White404585
More than one race000
Unknown or Not Reported112
Weight (kg)
Weight (kg)(Kilograms)ElinzanetantPlaceboTotal
Mean75.77 ± 12.4574.41 ± 10.6175.09 ± 11.53
Height (cm)
Height (cm)(Centimeters)ElinzanetantPlaceboTotal
Mean164.64 ± 7.08164.18 ± 7.01164.41 ± 7.02
Body Mass Index (kg/m2)
Body Mass Index (kg/m2)(Kilogram per square meter)ElinzanetantPlaceboTotal
Mean27.97 ± 4.3627.63 ± 3.7527.80 ± 4.05
Average weekly frequency of moderate to severe HF
Average weekly frequency of moderate to severe HF(Participants)ElinzanetantPlaceboTotal
<35 moderate to severe HF per week131124
>=35 - <50 moderate to severe HF per week111324
>=50 moderate to severe HF per week313162
Smoking
Smoking(Participants)ElinzanetantPlaceboTotal
Never404282
Former51015
Current10313

3 further baseline measures are reported on the registry.

08

Study locations

40 sites
  • Preferred Research Partners
    Little Port Walter, Alaska 72211, United States
  • MomDoc Women's Health Research | Scottsdale, AZ
    Scottsdale, Arizona 85251, United States
  • Diagnamics | Encinitas, CA
    Encinitas, California 92024, United States
  • SDS Clinical Trials Inc
    Santa Ana, California 92705, United States
  • Pacific Clinical Research Management Group LLC
    Upland, California 91786, United States
  • Helix Biomedics LLC | Boynton Beach, FL
    Boynton Beach, Florida 33435, United States
  • Sweet Hope Research Specialty, Inc. - Hialeah
    Hialeah, Florida 33016, United States
  • PharmaDev Clinical Research Institute, LLC
    Miami, Florida 33176, United States
  • Segal Trials - Women's Health & General Medicine Research Site
    North Miami, Florida 33161, United States
  • Palm Beach Research center
    West Palm Beach, Florida 33409, United States
  • Sleep Practitioners, LLC
    Macon, Georgia 31210, United States
  • SleepCare Research Institute Inc
    Stockbridge, Georgia 30281, United States
  • Brengle Family Medicine
    Indianapolis, Indiana 46260, United States
  • Revive Research Institute, Inc. - Women's Health
    Dearborn Heights, Michigan 48127, United States
  • Essential Women's Health Associates
    Las Vegas, Nevada 89113, United States
  • Clinilabs Drug Development Corporation-Feasibility
    Eatontown, New Jersey 07724, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Intrepid Research, LLC.
    Cincinnati, Ohio 45245, United States
  • Bogan Sleep Consultants, LLC
    Columbia, South Carolina 29201, United States
  • FutureSearch Trials of Neurology LP
    Austin, Texas 78731, United States
  • Sleep Therapy and Research Center | Medical Center Drive Office
    San Antonio, Texas 78229, United States
  • Road Runner Research, Ltd.
    San Antonio, Texas 78249, United States
  • EMCO Privatklinik
    Bad Dürrnberg, State of Salzburg 5422, Austria
  • Anima Research Center
    Alken, 3570, Belgium
  • SGS CPU
    Edegem, 2650, Belgium
  • Pneumocare SRL
    Erpent, 5101, Belgium
  • Universitair Ziekenhuis Leuven | Gasthuisberg Campus - Sleep Centre
    Leuven, 3000, Belgium
  • Národní ústav duševního zdraví
    Klecany, 250 67, Czechia
  • Siteworks - Zentrum für klinische Studien Hannover
    Hanover, Lower Saxony 30449, Germany
  • Klinische Forschung Dresden | Dresden, Germany
    Dresden, Saxony 01069, Germany
  • ADVANCED SLEEP RESEARCH BERLIN Berlin
    Berlin, 10117, Germany
  • KLIN FORSCHUNG HAMBURG GMBH Hamburg
    Hamburg, 20253, Germany
  • SOMNI BENE INSTITUT FUR MEDIZIMISCHE FORSCHUNG & SCHLAFMEDEZIN Schwerin
    Schwerin, 19053, Germany
  • Osrodek Medycyny Snu Instytutu Psychiatrii i Neurologii
    Warsaw, 02-957, Poland
  • EMC Instytut Medyczny SA
    Wroclaw, 50-220, Poland
  • Hospital Universitario de La Ribera | Neurophysiology and Sleep Department
    Alzira, 46600, Spain
  • Centro Medico Teknon | Unidad de Medicina del Sueno
    Barcelona, 08017, Spain
  • Hospital Clinico San Carlos | Neurophysiology Department - Sleep Unit - Menopause Sleep Disturbance
    Madrid, 28040, Spain
  • Hospital Universitario HM Puerta Del Sur | Departamento de Ensayos Clinicos - Sleep Unit - Menopause Sleep Disturbance
    Móstoles, 28938, Spain
  • Hospital Universitario de Araba | Santiago Campus - Unidad Sueno
    Vitoria-Gasteiz, 01009, Spain
09

References and documents

Publications

  • Baker FC, Joffe H, Soares CN, Maki PM, Bajbouj M, Nappi RE, Zammit G, Caetano C, Krahn U, Shalhoub H, Kramer F, Radcliffe HS, Seitz C. Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study. Sleep. 2026 Jul 28:zsag208. doi: 10.1093/sleep/zsag208. Online ahead of print. PubMed 42520241 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Aug 2024, 9 months.

Results were first posted in Nov 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Nov 1, 2023
StartActual
Nov 8, 2023
Primary completionActual
Aug 22, 2024
CompletionActual
Nov 7, 2024
Results first posted
Nov 10, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06112756
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Nov 8, 2023
Primary completion
Aug 22, 2024
Completion
Nov 7, 2024
Results posted
Nov 10, 2025
Last update
Nov 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion